期刊文献+

非高密度脂蛋白胆固醇与心脑血管疾病关系研究进展 被引量:4

Research Progress on Non-High-Density Lipoprotein Cholesteral and Cardiovascular and Cerebrovascular Diseases
下载PDF
导出
摘要 非高密度脂蛋白胆固醇(non-high-density lipoprotein cholesterol,non-HDL-C)反映致动脉粥样硬化胆固醇的总量,美国国家胆固醇教育计划中的成人治疗专家方案第3号报告中首次提出这一概念,并且将其作为降脂治疗的第二目标。目前已广泛证实non-HDL-C在冠状动脉粥样硬化性心脏病发病率及死亡率方面的预测价值较高,甚至可能优于传统血脂指标。但non-HDL-C与脑血管病相关的研究有限且结果存在争议,本文就non-HDL-C与心脑血管病相关的研究现状做一综述。 Non-high-density lipoprotein cholesterol (non-HDL-C) relfects the total amount of atherogenic cholesterol. The concept of non-HDL-C was ifrst proposed on the National Cholesteral Education Program Adult Treatment Panel III and was assigned to be the second target for lipid-lowering therapy. More and more recent studies at home and abroad have shown that the non-HDL-C could be a more accurate predictor of morbidity and morality of coronary atherosclerotic heart disease than traditional markers such as low density lipoprotein cholesterol. Currently, there are less and scattered research on the association between non-HDL-C and cerebrovascular diseases. This review aims to summarize and analyze the research progress of non-HDL-C.
作者 刘洋 郭阳
出处 《中国卒中杂志》 2015年第9期799-803,共5页 Chinese Journal of Stroke
关键词 非高密度脂蛋白胆固醇 低密度脂蛋白胆固醇 动脉粥样硬化 心血管疾病 脑血管疾病 Non-high-density lipoprotein cholesterol Low density lipoprotein cholesterol Atherosclerosis Cardiovascular diseases Cerebrovascular diseases
  • 相关文献

参考文献26

  • 1National Cholesterol Education Program Expert Panel. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adults Treatment Panel III)[J]. JAMA, 2001,285:2486-2497.
  • 2Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease[J]. Circulation, 2011, 123:2292-2333.
  • 3Allan S, Matt M, John C, et al. Why is non-high- density lipoprotein cholesterol a better marker of the risk of vascular disease than low-density lipoproteincholesterol[J]. J Cliu Lipidol, 2010, 4:152-155.
  • 4Rabar S, Harker M, O'Flynn N, et al. Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease:summary of updated NICE guidance[J]. BMJ, 2014, 349:356.
  • 5Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. J Am Coll Cardiol, 2013, 63:3024-3025.
  • 6Wu J, Chen S, Zhou Y, et al. Non-high-density lipoprotein cholesterol on the risks of stroke:a result from the Kailuan study[J]. PLoS One, 2013, 8:e74634.
  • 7Wu J, Chen S, Liu L, et al. Non-high-density lipoprotein cholesterol vs low-demity lipoprotein cholesterol as a risk factor for ischemic stroke:a result from the Kailuan study[J]. Neurol Res, 2013, 35:505-511.
  • 8Yun KH, Jeong MH, Oh SK, et al. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome[J]. Int Cardiol, 2009 137:246-251.
  • 9付文金,彭兰芬,叶长钦,蒋友明,程萍,李文忠.非高密度脂蛋白胆固醇与传统血脂指标的相关性分析[J].国际检验医学杂志,2007,28(8):705-707. 被引量:6
  • 10Study of the Effectiveness Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction:a double- blind randomized trial[J]. Lancet, 2010, 376:1658- 1669.

二级参考文献20

共引文献15

同被引文献39

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部